Table III.

Association between SPINK1 SNPs and prostate cancer risk.

Model	Rs10035432
	Genotype	Controls	* Cases	** OR (95% CI)	***p-Value
Co-dominant	G/G	65 (58%)	55 (58.5%)	1	0.44
	A/G	44 (39.3%)	33 (35.1%)	0.87 (0.44–1.71)
	A/A	3 (2.7%)	6 (6.4%)	0.35 (0.07–1.81)
Dominant	G/G	65 (58%)	55 (58.5%)	1	0.50
	A/G-A/A	47 (42%)	39 (41.5%)	0.80 (0.41–1.54)
Recessive	G/G-A/G	109 (97.3%)	88 (93.6%)	1	0.22
	A/A	3 (2.7%)	6 (6.4%)	0.38 (0.08–1.87)
Over-dominant	G/G-A/A	68 (60.7%)	61 (64.9%)	1	0.87
	A/G	44 (39.3%)	33 (35.1%)	0.95 (0.49–1.83)
Log-additive	---	---	---	0.75 (0.43–1.31)	0.31

Model	rs11748222
	Genotype	Controls	* Cases	** OR (95% CI)	***p-Value
Co-dominant	T/T	83 (79%)	63 (80.8%)	1	0.97
	C/T	15 (14.3%)	10 (12.8%)	1.10 (0.40–3.01)
	C/C	7 (6.7%)	5 (6.4%)	0.90 (0.23–3.49)
Dominant	T/T	83 (79%)	63 (80.8%)	1	0.96
	C/T-C/C	22 (20.9%)	15 (19.2%)	1.02 (0.44–2.40)
Recessive	T/T-C/T	98 (93.3%)	73 (93.6%)	1	0.86
	C/C	7 (6.7%)	5 (6.4%)	0.89 (0.23–3.42)
Over-dominant	T/T-C/C	90 (85.7%)	68 (87.2%)	1	0.85
	C/T	15 (14.3%)	10 (12.8%)	1.10 (0.40–3.02)
Log-additive	---	---	---	0.99 (0.55–1.79)	0.97

Model	rs1432982
	Genotype	Controls	* Cases	** OR (95% CI)	***p-Value
Co-dominant	A/A	69 (58.5%)	59 (61.5%)	1	0.48
	A/G	42 (35.6%)	27 (28.1%)	1.16 (0.59–2.30)
	G/G	7 (5.9%)	10 (10.4%)	0.53 (0.15–1.82)
Dominant	A/A	69 (58.5%)	59 (61.5%)	1	0.99
	A/G-G/G	49 (41.5%)	37 (38.5%)	1.00 (0.53–1.90)
Recessive	A/A-A/G	111 (94.1%)	86 (89.6%)	1	0.26
	G/G	7 (5.9%)	10 (10.4%)	0.50 (0.15–1.69)
Over-dominant	A/A-G/G	76 (64.4%)	69 (71.9%)	1	0.52
	A/G	42 (35.6%)	27 (28.1%)	1.25 (0.64–2.43)
Log-additive	---	---	---	0.89 (0.54–1.46)	0.65

^*Cases, included only PCa cases.

^**OR (95% CI): odd ratio and 95% confidential interval of SNP response to PCa when adjusted by age and %West African ancestry.

^***p-Value, adjusted p-value by age.